uniQure N.V.

QURE · Health care (pharmaceutical preparations) · 10 years of annual accounts filed with the SEC · latest fiscal year ended 2025-12-31

Signed in, this page also says what this company is inside your own portfolio: its weight, its share of your risk, and what buying or selling some of it would change. Sign in ›

uniQure N.V. reported revenue of $16.1 million in fiscal 2025, after shrinking 4.8% a year over the previous 9 years. Its operating margin narrowed from -286.7% in 2016 to -1151.4%, and it earned -76.7% on its invested capital in the latest year. On the accounting screens, it passes 4 of 9 Piotroski tests, its Altman Z'' of -1.71 is in the distress zone and its Beneish M-score is below the -1.78 line; 3 of the six cross-checks between its statements fire.

Revenue, fiscal 2025 16.1M -4.8% a year over 9 years

Operating margin -1151.4% gross margin 89.5%

Return on invested capital -76.7% -113.5% on average over 5 years

Free cash flow after stock pay -196.1M -1218.0% of revenue

Net debt ÷ EBITDA Net cash 30.5M more cash than debt

Piotroski F-score 4/9 tests of improvement passed

Is it growing?

Revenue and the operating income it turns into. Growth that does not reach operating income is growth bought with margin.

RevenueOperating income

Compound growth a year
	3 yrs	5 yrs	9 yrs
Revenue	-46.7%	-15.6%	-4.8%
Shares	+7.2%	+5.3%	+9.6%

Falling shares are buybacks: each remaining share owns more of the company.

Does it earn more than its capital costs?

Margins say how much of each sale is kept; return on invested capital says how much the business earns on the money it needs to operate. Growth only creates value when that return is above the cost of the capital.

    GrossOperatingNetFree cash flow
    
  

Return on invested capital

Economic profit

Needs a cost of capital, which comes from the valuation below.

Return on equity: -100.0%
Return on assets: -24.1%
Asset turnover: 0.02×
Research & development: 873.9% of revenue
Overheads (SG&A): 406.6% of revenue

Is the profit cash, and where does the cash go?

Net income is an accounting opinion; free cash flow is what was left in the bank after investing. Stock-based pay does not leave the bank — shareholders pay it through dilution — so it is shown taken off as well.

Net incomeFree cash flowAfter stock-based pay

Per share

    Earnings per shareFree cash flow per shareDividend per share
    
  

Shares outstanding

Diluted shares

How strong is the balance sheet?

Debt is not bad in itself; debt the business cannot service in a bad year is. Net debt is debt minus cash, and below zero the company holds more cash than it owes.

Net debt

Net debt ÷ EBITDA: 0.2×
Interest coverage: -3× operating income ÷ interest
Current ratio: 10.43 current assets ÷ current liabilities
Cash conversion cycle: —

Three classic screens of the accounts

Each asks a different question of the same statements — is it improving, does it look like a company heading for distress, do the accounts resemble ones that were manipulated. None is a verdict; each shows what moves it.

Piotroski F-score

Is the business improving? Nine yes-or-no tests, this year against last.

4of 9 tests passed

ProfitableReturn on assets above zero failed
Cash from operationsOperating cash flow above zero failed
Profitability improvedReturn on assets higher than a year before passed
Profit backed by cashOperating cash flow above net income (low accruals) passed
Less long-term debtLong-term debt as a share of assets fell passed
More liquidCurrent ratio higher than a year before passed
No new sharesShare count did not grow failed
Better gross marginGross margin higher than a year before failed
Sells more per assetAsset turnover higher than a year before failed

Where it misleads: it measures change, not level. An excellent business that stood still for a year scores low; a poor one recovering from a disaster scores high.

Altman Z''-score

Does the balance sheet look like those of companies that went bankrupt?

-1.71distress zone

Working capital ÷ assets 0.72 × 6.56+4.72
Retained earnings ÷ assets -1.61 × 3.26-5.25
Operating income ÷ assets -0.22 × 6.72-1.51
Equity ÷ liabilities 0.32 × 1.05+0.33

Where it misleads: buybacks. A company that returns so much cash that its equity turns small or negative sinks the last two ratios without being anywhere near bankruptcy. Banks and insurers do not fit the model at all.

Beneish M-score

Do the accounts resemble those of companies that manipulated their earnings?

-3.20below the -1.78 line

Receivables vs sales 1.00 (not reported, set to 1)+0.92
Gross margin slipping 1.06+0.56
Soft assets 0.72+0.29
Sales growth 0.59+0.53
Slower depreciation 0.74+0.09
Overheads vs sales 2.09-0.36
Profit not in cash -0.03-0.12
Leverage rising 0.83-0.27

Where it misleads: fast growth and acquisitions. Sales growth carries a heavy weight, so a company growing 50% a year scores like a suspect without having done anything. It is a screen from a 1999 study, not an accusation.

Where the statements disagree

Cross-checks between the income statement, the balance sheet and the cash flow for the latest year, each with the benign reading and the worrying one.

Reported profit comfortably exceeds the cash generated (-199M against -178M).

Benign

Growth consuming working capital, or the seasonality of the year-end.

Worrying

Profit held up by accounting entries that do not turn into money.

Capital spending (0M) is well below depreciation (15M).

Benign

Mature assets, or a business that has become less capital-intensive.

Worrying

Under-investing: today's profit is being held up by consuming tomorrow's capacity.

The effective tax rate is -2.9%.

Benign

A favourable geographic mix, or legitimate tax credits.

Worrying

Not sustainable; projecting it forward inflates the valuation.

What is it worth, under which assumptions?

A company is worth the cash it will generate, brought back to today. This model projects revenue with growth that fades over the years, applies a free cash flow margin, and discounts the result at the cost of capital. Every assumption says where it came from, and all of them can be changed.

Revenue

Starting revenue

M $

revenue of fiscal 2025

Growth in year one

revenue grew -15.6% a year over the last 5 years; it fades to the terminal rate by the last year

Years until it settles

yrs

ten years for growth to fade to the terminal rate

Cash from each sale

Free cash flow margin today

free cash flow to the firm after stock-based pay ÷ revenue, last 3 fiscal years together

Margin in the last year

the margin in year ten; by default the business keeps today's

Count stock-based pay as a costIt is paid in shares instead of cash, and shareholders bear it through dilution. Most free cash flow figures leave it out.

The long run

Growth after that, forever

growth forever after year ten, below the risk-free rate: no company outgrows the economy forever

The discount rate

Risk-free rate

10-year US Treasury par yield (U.S. Treasury), 2026-09-25

Beta

not measured on this public page, which uses only public filings: 1.0 assumes it moves like the market. Sign in to measure it from prices

Equity risk premium

the extra return demanded for holding shares; it cannot be measured, and 4–6% is the common range

Cost of debt, before tax

interest expense ÷ debt = 124.7%, kept between the risk-free rate and +8 points

Tax rate

effective rate in the last fiscal year, -2.9%, kept within 0–35%

The price

Share price

Type the price you see at your broker. It is used only for the reverse questions: what that price implies.

Back to the defaults

SEC from the filings Treasury the 10-year yield measured from prices assumption cannot be measured yours you changed it

With a free cash flow margin at or below zero in year ten, the business never generates cash for its owners and a DCF says nothing useful. Set a positive margin for year ten to see what it would take.

What it has filed lately

The last twelve months at the SEC, most important first: annual and quarterly reports, events, large holders and insiders.

Event 2026-09-02

Published information for investors

Signed a material agreement; published other information

Published information for investors; published other information

Event 2026-06-17

Published other information

Estimatein 36d

Results for the period ending 2026-09-29

What its own directors and officers did

Every Form 4 filed in the last twelve months, read line by line: 6 filings by 3 people. Open-market purchases and sales are counted apart from awards, option exercises and shares withheld for taxes.

Bought on the open market—none in the period

Sold on the open market$14.5M18 sale(s) by 3 insider(s)

Under pre-arranged plans94%of the sales followed a 10b5-1 plan set months earlier

Other lines80 awards · 8 option exercises · 0 tax withholdings

Date	Who	What	Shares	Price	Value	Holds after
2 Jul 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	9,200	$44.43	$408,756	531,109
2 Jul 2026	Kapusta Matthew CCEO, Managing Director	Exercised options	21,082	$19.39	$408,780	540,309
2 Jul 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	4,282	$45.43	$194,531	526,827
2 Jul 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	7,600	$45.89	$348,764	519,227
30 Jun 2026	Abi-Saab WalidChief Medical Officer	Exercised options	10,000	$5.59	$55,900	178,235
30 Jun 2026	Abi-Saab WalidChief Medical Officer	Sold on the open market · pre-arranged plan	10,000	$46.46	$464,600	168,235
30 Jun 2026	Abi-Saab WalidChief Medical Officer	Sold on the open market · pre-arranged plan	20,000	$46.40	$928,000	148,235
30 Jun 2026	Kaye JackDirector	Exercised options	4,107	$37.00	$151,959	30,103
30 Jun 2026	Kaye JackDirector	Sold on the open market · pre-arranged plan	4,107	$46.49	$190,934	25,996
30 Jun 2026	Kaye JackDirector	Exercised options	17,060	$20.18	$344,271	43,056
30 Jun 2026	Kaye JackDirector	Sold on the open market · pre-arranged plan	17,060	$46.43	$792,096	25,996
26 Jun 2026	Abi-Saab WalidChief Medical Officer	Sold on the open market	1,434	$46.86	$67,197	168,235
25 Jun 2026	Kapusta Matthew CCEO, Managing Director	Exercised options	28,716	$31.71	$910,584	547,943
25 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	28,716	$50.02	$1.4M	519,227
24 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	6,696	$50.00	$334,800	519,227
24 Jun 2026	Kapusta Matthew CCEO, Managing Director	Exercised options	4,128	$31.71	$130,899	525,923
18 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	4,656	$50.00	$232,800	558,810
18 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	37,015	$50.00	$1.9M	521,795
18 Jun 2026	Kapusta Matthew CCEO, Managing Director	Exercised options	4,656	$31.71	$147,642	563,466
17 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	56,929	$43.43	$2.5M	603,729
17 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	33,334	$45.01	$1.5M	570,395
17 Jun 2026	Kapusta Matthew CCEO, Managing Director	Exercised options	62,581	$19.39	$1.2M	723,239
17 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	11,585	$48.65	$563,610	558,810
17 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	23,977	$42.61	$1.0M	699,262
17 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	6,023	$43.70	$263,205	693,239
17 Jun 2026	Kapusta Matthew CCEO, Managing Director	Sold on the open market · pre-arranged plan	32,581	$45.02	$1.5M	660,658

A Form 4 says what happened, when, how many shares and at what price. It does not say why: a sale can be diversification, a tax bill or a plan fixed months earlier, and an award is pay, not a purchase. Nothing here is a reason to buy or sell anything.

Which large funds report holding it

From the Form 13F of the 28 institutions followed on this site, as of the end of their last reported quarter. A 13F is filed up to 45 days later and shows only long positions in US-listed shares.

Fund	Shares	Value	Share of the fund	Since the quarter before
Maverick Capital 30 Jun 2026	925,383	$42.6M	0.4%	Added to
Tudor Investment 30 Jun 2026	328,889	$15.1M	0.1%	New

All the funds and what they reported ›

Companies like this one

Same SEC industry (pharmaceutical preparations) first, then the rest of health care.

LLY ELI Lilly & Co JNJ Johnson & Johnson ABBV AbbVie Inc.MRK Merck & Co., Inc.ABT Abbott Laboratories PFE Pfizer Inc VRTX Vertex Pharmaceuticals Inc / MA BMY Bristol Myers Squibb Co

Every figure, year by year

10 fiscal years · 30 measures

	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Size
Revenue	25.1M	13.1M	11.3M	7.3M	37.5M	524.0M	106.5M	15.8M	27.1M	16.1M
Revenue growth	—	-47.8%	-13.9%	-35.5%	+415.2%	+1296.8%	-79.7%	-85.1%	+71.2%	-40.6%
Operating income	-71.9M	-71.3M	-88.2M	-121.1M	-125.4M	310.6M	-143.2M	-282.9M	-184.3M	-185.3M
Net income	-73.4M	-79.3M	-83.3M	-124.2M	-125.0M	329.6M	-126.8M	-308.5M	-239.6M	-199.0M
Margins
Gross margin	94.6%	93.8%	89.3%	77.3%	92.3%	95.2%	98.8%	99.6%	95.3%	89.5%
Operating margin	-286.7%	-544.3%	-781.9%	-1663.8%	-334.3%	59.3%	-134.4%	-1785.5%	-679.6%	-1151.4%
Net margin	-292.3%	-604.7%	-738.2%	-1705.8%	-333.3%	62.9%	-119.1%	-1947.1%	-883.4%	-1236.0%
Free cash flow margin	-348.5%	-524.4%	-695.0%	-1433.0%	-378.8%	51.6%	-152.8%	-966.3%	-686.2%	-1108.2%
R&D ÷ revenue	288.9%	550.6%	663.0%	1301.2%	326.3%	27.4%	185.6%	1356.2%	530.2%	873.9%
SG&A ÷ revenue	103.6%	188.0%	224.3%	460.7%	113.5%	10.7%	51.7%	470.8%	194.2%	406.6%
Cash
Free cash flow	-87.5M	-68.7M	-78.4M	-104.3M	-142.1M	270.5M	-162.7M	-153.1M	-186.1M	-178.4M
Stock-based pay	6.2M	10.3M	10.7M	17.5M	21.8M	25.6M	34.2M	35.1M	22.3M	17.7M
Free cash flow after stock pay	-93.7M	-79.0M	-89.1M	-121.9M	-163.9M	244.9M	-197.0M	-188.2M	-208.4M	-196.1M
Free cash flow to the firm	-82.9M	-68.4M	-78.4M	—	-136.6M	297.5M	-154.0M	-289.4M	-176.9M	-176.4M
Free cash flow ÷ net income	1.2×	0.9×	0.9×	0.8×	1.1×	0.8×	1.3×	0.5×	0.8×	0.9×
Capex ÷ revenue	60.9%	34.0%	21.1%	77.6%	19.4%	3.3%	16.6%	45.2%	12.4%	2.7%
Returns
Return on invested capital	-87.1%	-64.9%	-41.1%	—	-50.1%	44.2%	-25.0%	-92.0%	-417.7%	-76.7%
Return on equity	-115.3%	-88.7%	-46.4%	-38.4%	-51.3%	55.3%	-26.6%	-148.5%	—	-100.0%
Return on assets	-38.6%	-37.8%	-30.4%	-27.7%	-36.7%	40.7%	-18.0%	-37.1%	-43.0%	-24.1%
Asset turnover	0.1×	0.1×	0.0×	0.0×	0.1×	0.6×	0.2×	0.0×	0.0×	0.0×
Economic profit	—	—	—	—	—	—	—	—	—	—
Per share
Earnings per share	$-2.91	$-2.53	$-2.23	$-3.11	$-2.81	$7.04	$-2.71	$-6.47	$-4.92	$-3.46
Free cash flow per share	$-3.46	$-2.19	$-2.10	$-2.61	$-3.20	$5.78	$-3.48	$-3.21	$-3.83	$-3.10
Dividend per share	—	—	—	—	—	—	—	—	—	—
Payout ratio	—	—	—	—	—	—	—	—	—	—
Book value per share	$2.52	$2.85	$4.81	$7.39	$5.45	$12.87	$10.13	$4.34	$-0.14	$3.19
Diluted shares	25.3M	31.3M	37.4M	40.0M	44.5M	46.8M	46.7M	47.7M	48.6M	57.5M
Balance sheet
Net debt	-112.3M	-138.6M	-199.4M	-341.7M	-209.3M	-455.3M	-125.2M	-139.6M	-107.6M	-30.5M
Net debt ÷ EBITDA	1.7×	2.2×	2.6×	3.0×	1.8×	-1.4×	0.9×	0.5×	0.6×	0.2×
Interest coverage	-33.1×	-32.0×	-40.8×	-31.8×	-32.8×	41.6×	-12.2×	-6.8×	-2.9×	-3.0×
Current ratio	6.3×	8.5×	11.8×	12.1×	9.5×	17.1×	6.3×	8.8×	9.7×	10.4×
Cash conversion cycle (days)	—	—	—	—	—	—	—	—	—	—
Scores
Piotroski F-score	—	4	3	4	2	6	2	4	4	4
Altman Z''	-4.62	-4.41	-1.35	1.25	-2.87	8.47	1.86	-0.87	-4.73	-1.71
Beneish M	—	-3.32	-3.01	-2.34	1.63	9.65	-3.71	-5.68	-1.92	-3.20

Accounts from the company's own SEC filings; lines some companies do not report are shown as a dash rather than estimated. The risk-free rate is the 10-year US Treasury yield. A DCF is a way of making assumptions explicit, not a forecast: it states what the company would be worth if the assumptions held. The scores are screens that point where to look, not verdicts. Nothing here is a recommendation to buy or sell.